simmitinib + irinotecan liposome (Shanghai Runshi Pharmaceutical Technology Co., Ltd.)

Simmitinib + irinotecan liposome is a combination therapy being developed by Shanghai Runshi Pharmaceutical Technology for the treatment of advanced esophageal squamous cell carcinoma (ESCC). Simmitinib (also known as RS1805) is an orally bioavailable, multi-targeted small molecule tyrosine kinase inhibitor that primarily targets the vascular endothelial growth factor receptors (VEGFR1/2/3), platelet-derived growth factor receptors (PDGFRα/β), and c-Kit, thereby inhibiting tumor angiogenesis and proliferation. Irinotecan liposome is a nanoparticle-encapsulated formulation of the cytotoxic agent irinotecan, which acts as a topoisomerase I inhibitor to prevent DNA religation, leading to double-strand breaks and cell death. This combination is currently in Phase II clinical trials for patients with advanced ESCC who have progressed after first-line therapy, aiming to provide a more effective second-line treatment option by combining anti-angiogenic and cytotoxic mechanisms.

Other names

simmitinib plus irinotecan liposome